Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.55
+0.23003.14%
Post-market: 7.47-0.0800-1.06%17:10 EDT
Volume:1.73M
Turnover:13.30M
Market Cap:683.75M
PE:-3.13
High:7.91
Open:7.58
Low:7.54
Close:7.32
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.83
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.68
PE(LYR):-2.50

Loading ...

Verastem Initiated at Outperform by Wolfe Research

Dow Jones
·
Yesterday

Wolfe Research Initiates Verastem at Outperform

MT Newswires Live
·
Yesterday

Verastem initiated with an Outperform at Wolfe Research

TIPRANKS
·
Yesterday

Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target

TIPRANKS
·
Sep 12

Verastem Price Target Maintained with a $18.00/Share by BTIG

Dow Jones
·
Sep 11

Verastem Sets Oct. 14 Investor Event to Present New Vs-7375 KRAS G12D Trial Data Across Solid Tumors

Reuters
·
Sep 08

Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Verastem price target lowered to $13 from $14 at Mizuho

TIPRANKS
·
Aug 11

Verastem is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 08

Verastem - Enters Amendment No. 3 to Note Purchase Agreement on August 6, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 07

Verastem - Establishes Initial Notes of $75 Mln and Revenue Notes up to $75 Mln - SEC Filing

THOMSON REUTERS
·
Aug 07

Verastem Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Verastem Q2 Revenue Jumps on New Product Sales and Milestone

Reuters
·
Aug 07

Verastem Q2 FY26 GAAP Net Loss Widens to $34.67 Million; Revenue Rises to $40.08 Million

Reuters
·
Aug 07

Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate

Benzinga Earnings
·
Aug 07

Verastem Q2 Operating Expenses USD 72.788 Million

Reuters
·
Aug 07

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

THOMSON REUTERS
·
Aug 07

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

TIPRANKS
·
Jul 31

Verastem Oncology Doses First Patient in Target-D 203 Phase 2 Registration-Directed Trial of Vs-7375 Oral Kras G12d (on/off) Inhibitor for Kras G12d-Mutated Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jul 29

Verastem - Initiates Treatment in All Three Target-D Phase 2 Trials

THOMSON REUTERS
·
Jul 29